Unlock the potential of alpha-particle therapy for human health.
Alpha Fusion Inc. is a Japan-based clinical-stage biotech company commercializing Targeted Alpha Therapy (TAT) based on astatine-211 (211At). The company integrates expertise in radiochemistry, drug discovery, and clinical medicine to develop innovative radiopharmaceuticals that destroy cancer cells with precision while minimizing damage to surrounding healthy tissue. Alpha Fusion has multiple pipelines leveraging astatine-211, with two programs currently in clinical trials and company-sponsored trials planned from 2026. The company collaborates with Osaka University, Mitsubishi Tanabe Pharma, and Veneno Technologies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2023
Create a free account to see which investors have funded this company.
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
Biopharmaceutical company developing multispecific antibody therapies for retinal and complex dis...
